FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders

Key Takeaways

• FDA approves Jakafi XR, a once-daily extended-release formulation of ruxolitinib for three blood disorders
• New formulation provides day-long drug exposure comparable to twice-daily Jakafi with improved patient convenience
• Jakafi XR will be available for pharmacy orders starting May 8, 2024

---

The U.S. Food and Drug Administration has approved Incyte Corporation’s Jakafi XR™ (ruxolitinib) extended-release tablets for treating myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). This once-daily formulation represents a significant advancement in patient care for these rare blood disorders.

Enhanced Patient Convenience Through Extended-Release Technology

Jakafi XR is a film-coated, extended-release formulation of Incyte’s established JAK1/JAK2 inhibitor ruxolitinib. Clinical studies demonstrated that the once-daily extended-release tablets provide consistent, day-long drug exposure that is comparable to the twice-daily immediate-release Jakafi formulation currently on the market.

The approval addresses a key patient need for simplified dosing regimens in chronic conditions requiring long-term treatment. Myelofibrosis, polycythemia vera, and chronic GVHD are serious hematologic conditions that typically require ongoing therapy, making medication adherence crucial for optimal outcomes.

Market Impact and Competitive Positioning

This FDA approval strengthens Incyte’s position in the competitive JAK inhibitor market, where the company faces competition from Bristol Myers Squibb’s fedratinib, CTI BioPharma’s pacritinib, and GSK’s momelotinib. The extended-release formulation provides Incyte with a differentiated product offering that could help maintain market share as patent exclusivity periods approach.

The once-daily dosing convenience may appeal to both patients and healthcare providers, potentially driving adoption over twice-daily alternatives. This lifecycle management strategy extends the commercial viability of Incyte’s ruxolitinib franchise while providing genuine clinical value through improved dosing convenience.

Therapeutic Applications and Patient Populations

Jakafi XR maintains the same therapeutic indications as the original Jakafi formulation. For myelofibrosis patients, the drug helps reduce spleen size and alleviate debilitating symptoms. In polycythemia vera, it provides an alternative for patients who are resistant to or intolerant of hydroxyurea. For chronic GVHD, Jakafi XR offers treatment for patients who have failed corticosteroid therapy.

These conditions collectively affect thousands of patients in the United States, representing a significant market opportunity for Incyte. The improved dosing convenience could potentially expand the addressable patient population by reducing treatment burden.

Commercial Availability and Next Steps

Incyte has announced that Jakafi XR will be available for pharmacy orders beginning May 8, 2024. The company will likely focus on educating healthcare providers about the bioequivalence data supporting once-daily dosing and the potential benefits for patient adherence.

The approval represents successful execution of Incyte’s product lifecycle management strategy, potentially extending the commercial life of their ruxolitinib franchise while providing meaningful patient benefits through simplified dosing.

---

Frequently Asked Questions

What is the main difference between Jakafi XR and regular Jakafi?

Jakafi XR is an extended-release formulation taken once daily, while regular Jakafi requires twice-daily dosing. Both provide comparable drug exposure and efficacy for treating blood disorders.

When will Jakafi XR be available in pharmacies?

Jakafi XR will be available for pharmacy orders starting May 8, 2024, according to Incyte’s announcement following FDA approval.

Which conditions can be treated with Jakafi XR?

Jakafi XR is approved for treating myelofibrosis, polycythemia vera, and chronic graft-versus-host disease (GVHD), the same conditions as the original Jakafi formulation.